What is ?
is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly, marketed as (T2D) and Zepbound (obesity). In clinical trials it achieved approximately 20-22% body weight reduction — substantially higher than 's ~15%. It represents the current gold standard among approved GLP-1 class therapies, with the only compound showing higher efficacy in trials.
What makes mechanistically unique is the GIP component. GIP (glucose-dependent insulinotropic polypeptide) was initially considered a less important incretin, but research now shows that combined GLP-1/GIP agonism produces synergistic effects on both weight and metabolic markers that neither receptor achieves alone.
SURMOUNT-1 trial: 2,539 participants, 72 weeks, highest dose (15mg) achieved 22.5% mean weight loss vs 2.4% placebo. The largest weight reduction seen in any obesity pharmaceutical trial at the time of publication.
How the Dual Agonist Works
is a single molecule that activates both GLP-1 and GIP receptors. Unlike co-administration of two separate agonists, the single-molecule approach allows for optimized receptor activation kinetics and what researchers describe as "balanced" agonism at both receptors.
- GLP-1 activation: Slows gastric emptying, suppresses appetite via central nervous system pathways, increases insulin secretion, suppresses glucagon
- GIP activation: Potentiates insulin secretion, acts on adipose tissue to improve lipid metabolism, may enhance GLP-1 receptor expression (making GLP-1 activation more effective)
vs : Head to Head
The SURPASS-CVOT and SURMOUNT trials provide the most robust comparative data available:
- Weight loss: (22.5% at 15mg) outperforms (14.9% at 2.4mg)
- HbA1c reduction: Both show significant glycemic improvement; generally shows marginally greater reduction
- Cardiovascular outcomes: has SUSTAIN-6 and LEADER data; 's SURMOUNT-MMO cardiovascular outcomes trial is ongoing
- Side effect profile: Similar GI side effects; broadly comparable tolerability
For most research applications where efficacy is the primary variable, data currently favors it over .
Key Research Findings
- SURMOUNT-1 (2022): Primary obesity trial. 22.5% weight loss at 15mg vs 2.4% placebo, 72 weeks.
- SURPASS-2 (2021): Head-to-head vs 1mg in T2D. superior on all primary endpoints.
- SURPASS-CVOT: Ongoing cardiovascular outcomes trial.
- SURMOUNT-OSA (2024): 63% reduction in AHI (apnea-hypopnea index) in obstructive sleep apnea participants.
Research Dosing
Clinical trials used weekly subcutaneous injection with an escalation schedule:
- Weeks 1-4: 2.5mg weekly
- Weeks 5-8: 5mg weekly
- Weeks 9-12: 7.5mg weekly
- Weeks 13-16: 10mg weekly
- Maintenance: 10mg, 12.5mg, or 15mg weekly depending on response
This escalation schedule is specifically designed to minimize nausea and GI side effects. Jumping to higher doses without escalation significantly increases side effect burden in research subjects.
Where to Buy
The vast majority of available through research channels is imported — typically from Chinese API manufacturers with limited quality control. We've tested multiple batches from multiple sources and the variance is real. For research applications requiring reliable, consistent material, domestic US manufacturing matters.
UNYX Peptides manufactures their domestically at a GMP-certified facility — one of very few US-based sources. Their 10mg, 20mg, and 30mg vials are what we reach for when quality is non-negotiable.
- 100% USA-manufactured — GMP-certified Arizona facility (not imported from overseas)
- Third-party tested for purity — among the purest available in the US market
- Full catalog: GLP-1s, healing peptides, nootropics, longevity compounds
- Ships same or next business day — fastest fulfillment we've tested
- Bacteriostatic water in stock
- Subscribe & save on all products